Events and Fundraisers

Latest News

Harmony Biosciences Issues Statement Regarding Confidence in Pitolisant Drug

Harmony Biosciences has reaffirmed its confidence in the strength of WAKIX® (Pitolisant) patents, after receiving a positive ruling from the U.S. Patent and Trademark Office (USPTO) rejecting the request for reexamination. WAKIX® is used to treat excessive daytime sleepiness (EDS) or cataplexy in adults with Narcolepsy. Read Harmony Biosciences' community-facing statement below: We are pleased...

2023 Moms’ Retreat Attendees Selected!

Thank you to everyone who submitted an application to attend PWSA | USA's first-ever Moms' Retreat, October 12-15, 2023, in Palm Spring, California! On Friday, August 18, 2023, 30 applicants were randomly selected to attend the event. Our staff will be reaching out to these individuals to provide additional details and collect information. Below you...

Aardvark Therapeutics Announces FDA Pediatric Disease Designation for PWS, Expansion of Phase 2 Clinical Trial

Aardvark Therapeutics recently announced the drug company has received Pediatric Disease Designation for PWS from the U.S. Food and Drug Administration (FDA), and will expand its Phase 2 clinical trial of oral ARD-101 in young adults with PWS. According to Aardvark Therapeutics, this FDA designation means the company is eligible for a Rare Pediatric Disease...